{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-030708","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2024-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.062998+00:00","generated_at":"2026-05-31T23:44:52.293328+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ardelyx opts out of CMS TDAPA for XPHOZAH, foregoing add-on payment","bullets":["Ardelyx will not apply to include XPHOZAH (tenapanor) in CMS ESRD PPS TDAPA program.","Decision aimed at preserving patient access to the phosphate absorption inhibitor.","By opting out, XPHOZAH will not receive transitional add-on payment from Medicare.","Announcement made on July 2, 2024; no financial guidance provided on impact.","Company expects to rely on standard ESRD PPS bundled payment for XPHOZAH."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-030708","json":"https://secwatch.observer/filing/0001628280-24-030708.json","markdown":"https://secwatch.observer/filing/0001628280-24-030708.md","text":"https://secwatch.observer/filing/0001628280-24-030708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024030708/0001628280-24-030708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024030708/ardx-20240702.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:44:52.293328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}